- US-listed companies
- Aldeyra Therapeutics, Inc.
- Income statement
Aldeyra Therapeutics, Inc.ALDX
Market cap
$314.45M
P/E ratio
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Research & development | 4 | 8 | 13 | 16 | 30 | 44 | 25 | 45 | 47 | 29 | 48 |
| Operating income | -7,270,590 | -11,989,107 | -18,695,978 | -22,488,388 | -39,699,151 | -63,074,307 | -36,421,020 | -56,219,536 | -62,679,987 | -42,794,083 | -60,117,032 |
| Income before tax | - | - | - | - | - | -62,136,804 | -38,032,994 | -57,776,274 | - | - | - |
| Provision for income taxes | - | - | - | - | - | -1,309,973 | -479,265 | - | - | - | - |
| Effective tax rate (%) | - | - | - | - | - | - | - | - | - | ||
| Net income | -5,187,259 | -12,090,287 | -18,699,450 | -22,340,589 | -38,893,245 | -60,826,831 | -37,553,729 | -57,776,274 | -62 | -37 | -55,851,444 |
| Earnings per share | -2.51 | -1.4 | - | - | - | - | - | - | -1.06 | -0.64 | -0.94 |
| Diluted EPS | -3.09 | -1.4 | - | - | - | - | - | - | -1.06 | -0.64 | -0.94 |